The ever changing landscape of M&A Executive Summary Amid a streak of health care merger and acquisition (M&A) activity in 2018 and 2019, the Federal Trade Commission (FTC) is taking an aggressive stance in its review of biopharma deals Historically, FTC involvement in health care M&A was concentrated in ‘non-innovative’…
Microbiome and fecal transplant therapeutics Life sciences research continues to expand into new domains in the pursuit of innovative therapies. Along with this expansion comes a need for new regulations to ensure efficient and safe use of novel products. In the case of microbiome and fecal transplant therapeutics, the regulatory…
Key Takeaways Since its founding in 2006, ICER has become an influential organization in the drug pricing and US healthcare landscape ICER reports have been increasingly leveraged by payer organizations in coverage decisions; further, pharma has increasingly engaged with ICER when launching a product or announcing a new drug…
The CAR T- cell therapy revolution In 2017, the first therapy designed to genetically modify patients’ own T-cells to attack cancer was FDA-approved. These are known as CAR T-cell therapies. The therapies are an exceptional scientific advancement that have captured global attention due to their innovative nature. They have been…
CHN’s Quest to Encourage Pharma Entry Continues Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. Following their previous efforts to incentivize manufacturers to enter the Chinese market (easing evidence standards…
A brief history of NICE CBPartners’ take: The ultimate goal for both parties (manufacturers and NICE) is timely market access for patients as well as a return on investment. To achieve this there will need to be closer collaboration between both parties prior to receiving a recommendation about a new…
Summary The Central and Eastern Europe (CEE) region is attractive to drug manufacturers for its large cumulative population, evolving price and market access (P&MA) landscape, and relatively high willingness-to-pay (WTP) thresholds International Reference Pricing (IRP) policies continues to be one of the most important criteria in price decision-making in CEE…
Surveying the Field The story of CHN’s race to attract global investment into home-grown biotech begins in the USA. Since 2012, capital has flooded into the sector at unprecedented levels. Fueled by low interest rates and demand for high growth, USA biotech has experienced an explosion in private investment. Over…
SUMMARY Since the development of SINEMET in 1975, there has been little change in the standard of care for Parkinson’s disease given the high clinical failure rate of potential treatments partially driven by the inability of these compounds to pass the blood brain barrier Learning from the past failures, the…
SUMMARY Despite the high burden from Alzheimer’s disease, current therapies are only capable of managing the symptoms and experimental compounds designed to modify disease progression have failed clinical trials at an extremely high rate. The technologies available and capable of visualizing early AD signs are extremely expensive and there is…